Palisade Bio, Inc.

NasdaqCM:PALI Stock Report

Market Cap: US$3.2m

Palisade Bio Valuation

Is PALI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PALI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PALI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PALI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PALI?

Key metric: As PALI is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PALI. This is calculated by dividing PALI's market cap by their current book value.
What is PALI's PB Ratio?
PB Ratio0.5x
BookUS$6.61m
Market CapUS$3.19m

Price to Book Ratio vs Peers

How does PALI's PB Ratio compare to its peers?

The above table shows the PB ratio for PALI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.3x
LIPO Lipella Pharmaceuticals
2.3x3.3%US$3.6m
AZTR Azitra
0.5x-15.0%US$3.6m
ARAV Aravive
1.7xn/aUS$2.9m
ADTX Aditxt
0.6xn/aUS$3.5m
PALI Palisade Bio
0.5x-36.4%US$3.2m

Price-To-Book vs Peers: PALI is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.3x).

Price to Book Ratio vs Industry

How does PALI's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
PALI 0.5xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PALI is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.9x).

Price to Book Ratio vs Fair Ratio

What is PALI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PALI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PALI's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PALI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.42
US$30.33
+1,153.4%
52.9%US$45.00US$8.00n/a3
Nov ’25US$2.77
US$33.75
+1,118.4%
33.3%US$45.00US$22.50n/a2
Oct ’25US$3.45
US$33.75
+878.3%
33.3%US$45.00US$22.50n/a2
Sep ’25US$3.53
US$33.75
+856.1%
33.3%US$45.00US$22.50n/a2
Aug ’25US$3.65
US$33.75
+824.7%
33.3%US$45.00US$22.50n/a2
Jul ’25US$4.30
US$33.75
+684.9%
33.3%US$45.00US$22.50n/a2
Jun ’25US$4.82
US$33.75
+600.2%
33.3%US$45.00US$22.50n/a2
May ’25US$7.08
US$33.75
+376.7%
33.3%US$45.00US$22.50n/a2
Apr ’25US$5.85
US$33.75
+476.6%
33.3%US$45.00US$22.50n/a2
Mar ’25US$6.12
US$33.75
+451.5%
33.3%US$45.00US$22.50n/a2
Feb ’25US$8.80
US$33.75
+283.6%
33.3%US$45.00US$22.50n/a2
Jan ’25US$8.85
US$33.75
+281.4%
33.3%US$45.00US$22.50n/a2
Dec ’24US$9.08
US$33.75
+271.8%
33.3%US$45.00US$22.50n/a2
Aug ’24US$31.80
US$157.50
+395.3%
52.4%US$240.00US$75.00US$3.652
Jul ’24US$25.50
US$157.50
+517.6%
52.4%US$240.00US$75.00US$4.302
Jun ’24US$21.60
US$157.50
+629.2%
52.4%US$240.00US$75.00US$4.822
May ’24US$24.90
US$225.00
+803.6%
66.7%US$375.00US$75.00US$7.082
Apr ’24US$52.80
US$225.00
+326.1%
66.7%US$375.00US$75.00US$5.852

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%